Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Executive Summary
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.
You may also be interested in...
New Insulin Manufacturer For Civica
Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.
Biocon Knocked Back By FDA On Human Insulin
Biocon has seen its insulin-R application knocked back by the US FDA, with a complete response letter citing a need for more data as well as the need for remediation activities at its Bangalore facilities.
Biocon Closes $3bn Deal For Viatris Biosimilars
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.